Travere Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Travere Therapeutics (TVTX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

13Buy

2Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$49Upside to Avg. PT-25.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 10, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$68→$78
Aug 6, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$70
Aug 6, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$61→$75
Aug 5, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$60→$75
Aug 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$70→$85
Aug 5, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$60→$68
Aug 5, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$65→$75
Jul 30, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$56→$62
Jun 25, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$56→$65
Jun 22, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$55→$61
Jun 18, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	Outperform	$52→$60
Jun 15, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$62→$70
Jun 12, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$50→$65
Jun 3, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$59→$62
Jun 3, 2026	Wedbush	Laura Chico	Maintained	Outperform	$55
Jun 2, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$57→$67
May 6, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$40→$50
May 5, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$45→$60
May 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$53→$59
May 5, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$53→$55

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.

Benzinga Newsdesk

Travere Therapeutics Inc

Travere Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

PRO
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68

People Also Watch

People Also Watch

Travere Therapeutics Inc

Travere Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROEvercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

PROCanaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

PROWedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

PROTD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

PROCitigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

PROEvercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68

People Also Watch

People Also Watch

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

PRO
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68